Lipoprotein lipase releases esterified oxylipins from very low-density lipoproteins

We previously demonstrated that defects in lipoprotein metabolism alter the distribution of oxygenated polyunsaturated fatty acids (PUFAs) in lipoprotein particles. If these oxidation products are released by lipoprotein lipase (LpL), then their delivery to peripheral tissues with bulk lipids could influence cellular function. Using 26-week-old normolipidemic and hyperlipidemic Zucker rats, we measured PUFA alcohols, epoxides, diols, ketones, and triols (i.e. oxylipins) in esterified and non-esterified fractions of whole plasma, VLDL, and LpL-generated VLDL-lipolysates. Whole plasma, VLDL, and lipolysate oxylipin profiles were distinct and altered by hyperlipidemia. While >90% of the whole plasma oxylipins were esterified, the fraction of each oxylipin class in the VLDL varied: 46% of alcohols, 30% of epoxides, 19% of diols, <10% of ketones, and <1% triols. Whole plasma was dominated by arachidonate alcohols, while the linoleate alcohols, epoxides, and ketones showed an increased prevalence in VLDL. LpL-mediated VLDL lipolysis of PUFA alcohols, diols and ketones was detected and the relative abundance of oxygenated linoleates was enhanced in the lipolysates, relative to their corresponding VLDL. In summary esterified oxylipins were seen to be LpL substrates with heterogeneous distributions among lipoprotein classes. Moreover, oxylipin distributions are changes within the context of obesity-associated dyslipidemia. These results support the notion that the VLDL–LpL axis may facilitate the delivery of plasma oxylipins to the periphery. The physiological implications of these findings are yet to be elucidated; however, these molecules are plausible indicators of systemic oxidative stress, and could report this status to the peripheral tissues.     

高脂血症大鼠血小板活化功能分析

目的分析高脂血症大鼠血小板功能的变化。方法24只Wistar大鼠随机分为正常对照组、高脂血症模型组，4周后检测两组大鼠的血脂：总胆固醇（CHO）、甘油三酯（TG）、低密度脂蛋白胆固醇（LDL-C）、高密度脂蛋白胆固醇（HDL-C）水平。应用流式细胞术检测血小板表面a-颗粒膜糖蛋白（CD62P）的表达、酶联免疫法测定血浆中α颗粒膜蛋白．140（GMP140）浓度。所有数据采用Excel软件建库，SPSS11．5统计软件进行分析。结果正常对照组与高脂血症组CHO、TG、LDL-C、HDL-C，CHO分别是1．846mmol／L VS 13．779mmol／L、0．999mmol／L vs 0．746mmol／L、0．164mmol／L vs 10．680mmol／L、0．583mmol／L vs 0．195mmol／L。CD62P、GMP140水平分别为10．089％ vs 25．169％、10．665ng/mL vs 27．045．g／mL。结论高脂血症能够促使血小板活化。     

PROXISOME PROLIFERATOR-ACTIVATED RECEPTOR-α MEDIATES HIGH-FAT,DIET-ENHANCED DAILY OSCILLATION OF PLASMINOGEN ACTIVATOR INHIBITOR-1 ACTIVITY IN MICE

Acute thrombotic events frequently occur in the early morning among hyperlipidemic patients. The activity of plasminogen activator inhibitor-1 (PAI-1), a potent inhibitor of the fibrinolytic system, oscillates daily, and this is considered one mechanism that underlies the morning onset of acute thrombotic events in hyperlipidemia. Although several studies have reported the expression of the PAI-1 gene is under the control of the circadian clock system, the molecular mechanism of the circadian transactivation of PAI-1 gene under hyperlipidemic conditions remains to be elucidated. Here, the authors investigated whether hyperlipidemia induced by a high-fat diet (HFD) enhances the daily oscillation of plasma PAI-1 activity in mice. The mRNA levels of the PAI-1 gene were increased and rhythmically fluctuated with high-oscillation amplitude in the livers of wild-type mice fed with the HFD. Circadian expression of proxisome proliferator-activated receptor-α (PPARα) mRNA was also augmented as well as that of PAI-1. Chromatin immunoprecipitaion showed the HFD-induced hyperlipidemia significantly increased the binding of PPARα to the PAI-1 promoter. Luciferase reporter analysis using primary hepatocytes revealed CLOCK/BMAL1-mediated PAI-1 promoter activity was synergistically enhanced by cotransfection with PPARα/retinoid X receptor-α (RXRα), and this synergistic transactivation was repressed by negative limbs of the circadian clock, PERIOD2 and CRYPTOCHROME1. As expected, HFD-induced PAI-1 mRNA expression was significantly attenuated in PPARα-null mice. These results suggest a molecular link between the circadian clock and lipid metabolism system in the regulation of PAI-1 gene expression, and provide an aid for understanding why hyperlipidemia increases the risk of acute thrombotic events in the morning. (Author correspondence: ssoeda@fukuoka-u.ac.jp)     

PKB/ Akt 在高脂诱导鼠肾脏损害中的作用

目的:通过建立高脂血症大鼠模型,探讨单纯高脂对肾脏的损伤机制以及胰岛素传导通路中的关键酶PKB/Akt(丝氨酸/苏氨酸激酶)在高脂所致肾脏损害中的变化和意义。方法:高脂高胆固醇喂养Wistar雄性大鼠,建立胰岛素抵抗模型。分别在4周、8周、12周测定大鼠的肾功,包括血尿素蛋(BUN),肌酐(CREA);16周时测定甘油三酯(TG),胆固醇(TC),以及血糖(FBS)和胰岛素(FINS)。8周时行胰岛素增敏剂文迪雅(3mg/kg)灌胃干预四周,并行肾脏病理检查,应用免疫组化法监测PKB/Akt在肾脏的表达。结果:高脂喂饲大鼠4周后,进食量开始减少,体重增加减慢;血BUN、血CREA在4周时已升高,至8周时增加更明显(p<0.001)。文迪雅灌胃四周后肾功改善,但仍高于正常组(p<0.05)。血TG和血TC较正常组升高显著,统计学差异显著(p<0.05)。血胰岛素升高,但胰岛素敏感性降低,胰岛素抵抗指数增加显著,提示胰岛素抵抗形成。肾脏免疫组化PKB/Akt的表达呈现为在肾小球和肾小管分布不均,出现PKB/Akt在损伤较重的肾小球不表达,而在损伤较轻的肾小管表达减弱的现象。结论:饮食诱导的高脂血症可导致健康大鼠产生脂质肾毒性损害以及肾功的降低,并可产生胰岛素抵抗。胰岛素传导通路的损害在肾小球和肾小管表达不同,说明其可能是产生肾脏损伤及胰岛素抵抗的又一原因。胰岛素增敏剂可改善胰岛素抵抗及肾功。     

心脉通胶囊联合非诺贝特对饮食控制疗法效果不佳的高脂血症患者血脂、血液流变学和血管内皮功能的影响

摘要 目的：观察心脉通胶囊联合非诺贝特对饮食控制疗法效果不佳的高脂血症患者血脂、血液流变学和血管内皮功能的影响。方法：所选病例为我院2019年5月~2021年9月期间接诊的68例饮食控制疗法效果不佳的高脂血症患者。采用随机数字表法进行分组,68例患者共分为对照组和联合组,例数各为34例。对照组患者接受非诺贝特治疗,联合组患者接受心脉通胶囊联合非诺贝特治疗,对比两组临床总有效率、血脂、血液流变学和血管内皮功能,记录两组治疗期间不良反应发生情况。结果：联合组的临床总有效率高于对照组（P<0.05）。治疗2个月后,联合组的血清全血还原黏度、低密度脂蛋白胆固醇（LDL-C）、血管内皮素-1（ET-1）、血浆比黏度、甘油三酯（TG）、全血比黏度、总胆固醇（TC）、纤维蛋白原水平、血细胞比容水平低于对照组,降钙素基因相关肽（CGRP）、高密度脂蛋白胆固醇（HDL-C）、一氧化氮（NO）水平高于对照组（P<0.05）。两组不良反应发生率对比无统计学差异（P>0.05）。结论：心脉通胶囊联合非诺贝特治疗饮食控制疗法效果不佳的高脂血症患者,可有效控制血脂,调节血液流变学和血管内皮功能,应用价值较好。     

脂蛋白脂肪酶基因敲除对急性高脂血症性胰腺炎所致肺损伤的影响及其机制研究

摘要 目的：研究脂蛋白脂肪酶（lipoprotein lipase,LPL）基因敲除对雨蛙素诱导的高脂血症急性胰腺炎小鼠肺损伤的影响。方法：将C57BL/6小鼠分为三组,Control组和AP-Model组为野生型C57 BL/6小鼠,LPL ko组为LPL基因敲除C57 BL/6小鼠;Control组小鼠正常饲养,AP-Model和LPL ko组小鼠建立高脂血症性急性胰腺炎模型,比较三组小鼠死亡率、胰腺和肺病理损伤以及血清淀粉酶（amylase, AMY）、丙二醛（malondialdehyde, MDA）、肿瘤坏死因子-α（Tumor necrosis factor-α, TNF-α）和白介素-6（Interleukin-6, IL-6）含量。结果：急性胰腺炎建立48 h后,Control组、AP-Model组和LPL ko组小鼠死亡率分别为0 %、20 %和40 %。与Control组相比,AP-Model组和LPL ko组小鼠急性胰腺炎诱导24和48 h后的胰腺和肺组织湿/干重比值,胰腺和肺组织病理评分,血清AMY、MDA、TNF-α和IL-6含量均显著升高（P<0.05）;与AP-Model组相比,LPL ko组小鼠急性胰腺炎诱导24和48 h后的胰腺和肺组织湿/干重比值,胰腺和肺组织病理评分,血清AMY、MDA、TNF-α和IL-6含量均显著升高（P<0.05）。结论：LPL基因敲除小鼠急性高脂血症性胰腺炎肺损伤更严重,其机制可能与LPL基因敲除引起更强的氧化应激和炎症有关。     

大剂量瑞舒伐他汀钙治疗老年冠心病合并高脂血症的疗效观察

目的:研究大剂量瑞舒伐他汀钙治疗老年冠心病合并高脂血症的临床疗效。方法:选取2013年10月到2014年10月我院收治的老年冠心病合并高脂血症患者110例,按照随机数字表法将患者分为研究组和对照组,每组55例。两组患者均给予常规治疗方法进行治疗,对照组增加5 mg瑞舒伐他汀钙进行治疗,研究组增加20 mg瑞舒伐他汀钙进行治疗,均每天1次,晚餐后应用,治疗时间为4个月。比较治疗前后两组血脂水平(胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白(LDL-C))及高密度脂蛋白(HDL-C)及其达标率以及不良反应。结果:治疗后两组TC、TG以及LDL-C均显著降低,HDL-C显著升高,且研究组优于对照组,比较差异具有统计学意义(P0.05);研究组治疗后TC和LDL-C达标率显著高于对照组,两组比较差异具有统计学意义(P0.05);两组不良反应发生率比较差异无统计学意义(P0.05)。结论:大剂量瑞舒伐他汀钙治疗老年冠心病合并高脂血症具有较好的临床疗效,能显著降低患者的血脂水平。     

肠球菌WZM05对高胆固醇血症小鼠载脂蛋白的影响

目的探讨肠球菌WZM05对高胆固醇血症小鼠血清学指标及高胆固醇血症形成的影响。方法采用灌胃法建立小鼠高胆固醇血症模型及肠球菌实验组（10^6、10^8、10^9CFU／m1）,实验40d后,进行血清血脂水平检测及载脂蛋白A1（apoAI）、载脂蛋白B（apoB）测定。结果肠球菌组的血清总胆固醇明显降低,高密度脂蛋白明显升高（P〈0．01）,血清apoAI升高及apoB降低（P〈0．05）。结论肠球菌WZM05具有降脂、调脂作用。     

血脂康胶囊对高脂模型大鼠EPCs功能的影响

目的:高脂血症可增加心血管事件的发生率,本研究降脂红曲制剂血脂康胶囊对高脂模型大鼠的内皮祖细胞(endothelial progenitor cells,EPCs)生物学功能的影响。方法:给予Wistar大鼠高脂饲料30 d,造成高血脂大鼠模型,灌服血脂康胶囊。密度梯度离心法分别分离正常对照组,高脂模型组和血脂康治疗组大鼠骨髓单核细胞,应用EGM-2MV进行体外培养。以4~6代EPCs为靶细胞。采用Edu标记技术、CCK-8检测法、粘附能力测定试验、改良的Boyden小室、Matrigel法、荧光定量RT-PCR等方法分别检测EPCs增殖、粘附、迁移、体外成血管及单核细胞趋化蛋白-1(monocyte chemoattractant protein-1,MCP-1)等炎性因子的表达。结果:高血脂模型组大鼠EPCs的增殖、粘附、迁移及成血管能力均明显低于对照组,但炎症因子MCP-1表达则高于对照组;与高脂模型组EPCs比较,血脂康可明显促进EPCs的增殖、粘附、迁移及成血管,下调MCP-1的表达。结论:高脂状态下大鼠EPCs的增殖、粘附、迁移及成血管等生物学功能受损,血脂康能调整脂质代谢,改善高脂血症大鼠EPCs功能,从而起到保护血管内皮的功能,减少心血管疾病的发生。     

阻塞型睡眠呼吸暂停低通气综合征与代谢综合征组分关系探讨

目的:探讨阻塞型睡眠呼吸暂停低通气综合征(OSAHS)与代谢综合征(MS)组分关系。方法:对我院2003年1月至2010年7月39例诊断为OSAHS住院患者进行回顾性调查,30例同期住院病人为对照组,均记录年龄、性别,测量身高、体重、血压,检测空腹血糖、血脂,分析OSAHS患者合并MS组分情况。结果:1.OSAHS组与对照组比较,体重指数(BMI)、血压、血清甘油三酯、总胆固醇、低密度脂蛋白胆固醇、载脂蛋白A1升高,高密度脂蛋白胆固醇降低(P<0.05);2.OSAHS组与对照组相比较,无MS组分比例低于对照组,差异有统计学意义(P<0.05);3.OSAHS组与对照组相比较,OSAHS组合并MS组分,包括BMI≥25Kg/m2,血脂紊乱的比例,均高于对照组,差异有统计学意义(P<0.05)。结论:OSAHS患者易合并代谢综合征组分。